NLM Gateway
A service of the U.S. National Institutes of Health
Your Entrance to
Resources from the
National Library of Medicine
    Home      Term Finder      Limits/Settings      Search Details      History      My Locker        About      Help      FAQ    
Skip Navigation Side Barintended for web crawlers only

HIV immunization and challenge of HIV seropositive and seronegative chimpanzees.

Peters R, Jensen FC, Carla DJ, Salk J; International Conference on AIDS.

Int Conf AIDS. 1989 Jun 4-9; 5: 541 (abstract no. Th.C.O.46).

NIH, Bethesda, MD, USA

OBJECTIVE: To determine the characteristics of the serologic response of HIV seropositive and seronegative chimpanzees to HIV immunization and to virus challenge. METHODS: Three adult chimpanzees (two seropositive and one seronegative) were inoculated I.M. (primary and 2 booster doses) with a gamma irradiated non-infectious HIV immunogen emulsified in incomplete Freund's adjuvant (IFA). Approximately 13-15 months after the initial immunization, these chimpanzees and an untreated control animal were challenged I.V. with 10 chimpanzee infectious doses of HIV. Western blots, ELISA's and tests for neutralizing antibody and for virus by co-cultivation of PBL were performed. RESULTS: The two previously HIV infected seropositive chimpanzees, A-86C and A-3, exhibited an anamnestic response to the first dose of immunogen; the initially seronegative animal, A-36, manifested a primary- and secondary-type response after the first and second doses, respectively. After challenge, A-86C and A-3 exhibited no evidence of infection virologically or serologically. In contrast, A-36 became virus positive after challenge and responded anamnestically to infection with a rise in anti-p24 antibody titer from 1:16,000 to 1:256,000. The control chimpanzee, A-189a, also became virus positive and exhibited only a primary-type antibody response to the virus infection (anti-p24 titer from negative to 1:8000). CONCLUSION: 1) The resistance to reinfection observed in A-86C and A-3 suggests that the induction of immunity to infection by potentiating a noninfectious immunogen may be an attainable goal. 2) The anamnestic response following challenge observed in A-36, in contrast to the primary-type response to infection observed in A-189a, raises the possibility that induction of immunity to disease, through vaccine-induced immunologic memory, may be achieved even if infection is not prevented.

Publication Types:
  • Meeting Abstracts
Keywords:
  • AIDS Vaccines
  • Acquired Immunodeficiency Syndrome
  • Animals
  • Blotting, Western
  • Enzyme-Linked Immunosorbent Assay
  • HIV Infections
  • HIV Seropositivity
  • Immunization
  • Pan troglodytes
  • Vaccination
  • methods
Other ID:
  • 00280189
UI: 102178703

From Meeting Abstracts




Contact Us
U.S. National Library of Medicine |  National Institutes of Health |  Health & Human Services
Privacy |  Copyright |  Accessibility |  Freedom of Information Act |  USA.gov